Glenmark Pharma surges as Nomura raises target price, sees 50% upside
Nomura has a 'buy' rating for Glenmark Pharma with a target price of Rs 63314-02-2023
14-02-2023
Glenmark Pharmaceuticals Results Earnings Call for Q3FY23
Conference Call with Glenmark Pharmaceuticals Management and Analysts on Q3FY23 Performance and Outlook. Listen to the full earnings transcript.13-02-2023
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to the Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby confirm that we have uploaded audio recording of Q3 of FY 2022-23 Earnings Call held on 13th February, 2023 on the website of the Company.13-02-2023
Glenmark Pharma jumps 5% post December quarter earnings
The company reported a 21 per cent surge in Q3 consolidated net at Rs 291 crore.13-02-2023
Glenmark Pharma December quarter PAT rises by 21.3% to Rs 290.8 crore
Glenmark Pharmaceuticals Ltd on Friday reported a 21.3 per cent rise in consolidated profit after tax at Rs 290.8 crore for the third quarter ended December 31, 2022. The company had posted a consolidated consolidated profit after tax of Rs 239.8 crore in the corresponding quarter last fiscal, Glenmark Pharma said in a statement. Consolidated revenue was at Rs 3,463.9 crore, as against Rs 3,173.4 crore, up 9.2 per cent, it added. "We had yet another quarter with a strong performance led by robust growth across all our markets despite the challenging macroeconomic conditions," Glenmark Pharmaceuticals Chairman & Managing Director Glenn Saldanha said. The company's India business continued to record a healthy increase in secondary sales, while the US business recovered well as the year progressed and the rest of world and EU businesses also reflected formidable growth during the quarter, he added. Sales from the India formulation business in the third quarter were at Rs 1,074.5...10-02-2023
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Change in Management
Based on the recommendation of the Nomination and Remuneration Committee, the Board of the Company at its Meeting held today has approved the appointment of Mrs. Vijayalakshmi Rajaram Iyer (DIN: 05242960) as an Additional Director designated as Non-Executive - Independent, not liable to retire by rotation, effective today i.e. February 10, 2023.10-02-2023
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Investor Presentation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the Investor Presentation Q3 FY23.10-02-2023
GLENMARK PHARMACEUTICALS LTD. - 532296 - Unaudited Financial Results (Standalone And Consolidated) For The Third Quarter And Nine Months Ended December 31, 2022
Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that Board has today at its meeting, approved the Unaudited Financial Results for the Third Quarter and Nine Months ended December 31, 2022. The said meeting of the Board commenced at 2.00 p.m. and concluded at 7.25 p.m. The copy of the said results together with Management Discussion & Analysis, Press Release and Limited Review Report of the Auditors is enclosed herewith. These are also being made available on the website of the Company.10-02-2023
GLENMARK PHARMACEUTICALS LTD. - 532296 - Update On The Company''s Baddi (India) Facility
Update on the Company''s Baddi (India) Facility27-01-2023
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark launches AKYNZEO(r) I.V. in India - First Fixed I.V. Antiemetic Combination for the Prevention of Chemotherapy-induced Nausea and Vomiting23-01-2023